Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;20(4):342-348.
doi: 10.5213/inj.1632628.314. Epub 2016 Dec 26.

The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea

Hoon Choi  1 , Hong Chung  2 , Jae Young Park  1 , Jeong Gu Lee  1 , Jae Hyun Bae  1
Affiliations

The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea

Hoon Choi et al. Int Neurourol J. 2016 Dec.

Abstract

Purpose: The goal of this study is to investigate the effects of androgen deprivation therapy (ADT) on total prostate volume and lower urinary tract symptoms (LUTS).

Methods: Between January 2007 and June 2014, 110 patients who received androgen deprivation treatment were enrolled in this retrospective study. Clinical parameters and urodynamic parameters along with changes at follow-up were analyzed. Factors such as reduction in prostate volume, changes in LUTS, and prostate volume tertiles were compared 1 year after ADT.

Results: After ADT, the total International Prostate Symptom Score (IPSS) score decreased from 17.45 to 12.21 and the IPSS voiding subscore decreased from 9.16 to 6.24. Maximal uroflow rate increased from 8.62 to 11.50 mL/sec and residual urine also reduced significantly by 29.34 mL. Change in prostate size was more prominent (-51.14%) in the patients with less than 1 year of ADT (n=21) than those who had more than 1 year of treatment (n=89, -44.12%). The decrease in the IPSS voiding subscore was greater within 1 year of ADT than after 1 year of treatment (-4.10 vs. -2.65). The differences were more significant in the 30-50 g group (n=59) and >50 g group (n=11) than the <30 g group (n=40) of the IPSS voiding subscore improvement (-3.76 , -4.91 vs. -2.10), and maximal uroflow rate improvement (2.78, 2.90 vs 1.49).

Conclusion: ADT resulted in statistically significant clinical improvement in terms of prostate volume, urodynamic parameters, and LUTS for patients with prostate cancer when analyzed by ADT duration and prostate volume.

Keywords: Androgen Deprivation Therapy; Prostate Neoplasms; Prostate Volume.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

References

    1. Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev. 2005;26:361–79. - PubMed
    1. Sanghani MV, Schultz D, Tempany CM, Titelbaumd D, Renshawe AA, Loffredoa M, et al. Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen deprivationtherapy in patients with prostate cancer. Urology. 2003;62(3 Suppl):487–91. - PubMed
    1. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–98. - PubMed
    1. Cho KJ, Kang SH, Kim HS, Koh JS, Kim JC. Effect of 5-alpha reductase inhibitor on storage symptoms in patients with benign prostatic hyperplasia. Int Neurourol J. 2011;15:152–7. - PMC - PubMed
    1. Hamilton W, Sharp D. Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract. 2004;54:617–21. - PMC - PubMed

LinkOut - more resources